Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy
Sunati Sahoo(The University of Texas Southwestern Medical Center), Idris Tolgay Ocal(Mayo Clinic in Arizona), Jodi M. Carter(University of Alberta), Sonal Shad(University of California, San Francisco), Laila Khazai(Moffitt Cancer Center), Emily Reisenbichler(Saint Louis University), Yunn‐Yi Chen(University of Vermont), Sara J. Venters(University of California, San Francisco), Alexander D. Borowsky(University of California, San Francisco), Ronald Balassanian, Beiyun Chen(Mayo Clinic), Hanina Hibshoosh, Hua Guo(Zhengzhou University), Fang Fan(University of Kansas Medical Center), Gregor Krings(Cleveland Clinic), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Molly Klein(University of Minnesota), Shi Wei(University of Alabama at Birmingham)
Cited by 16
Related Papers
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
A molecular single-cell lung atlas of lethal COVID-19
|Nature|2021|735